Sight Diagnostics

Company Overview

Snapshot

Founded in September 2010 by Daniel Levner and Yossi Pollak, Sight Diagnostics operates with 51–200 employees. The company has raised $123.8M across 5 funding rounds from 13 investors. In May 2024, Sight Diagnostics announced a workforce reduction of 40 employees, representing 30% of its staff.

Business overview

Sight Diagnostics specializes in advanced blood diagnostics, leveraging computer vision and machine learning technologies. Its core offerings include the Parasight platform for malaria diagnosis and the OLO analyzer, a point-of-care complete blood count (CBC) platform that delivers lab-grade results rapidly. The company's technology is designed to provide accurate and inexpensive testing for various diseases, serving doctors' offices, emergency medical centers, and laboratories within the health tech and life sciences sectors.

Strategic signal

Sight Diagnostics is undergoing a significant operational restructuring, as evidenced by the May 2024 announcement of a 30% workforce reduction. This move, following the founder's departure and a reported scaling back of core development, signals a challenging period for the company, prompting investors to assess its strategic direction and financial stability.

Company Intelligence Q&A

What was a significant operational change at Sight Diagnostics in 2024?

In May 2024, Sight Diagnostics announced a reduction of 40 employees, which constituted 30% of its workforce. This followed the departure of a founder and a reported scaling back of the company's main development efforts.

What was the latest funding round for Sight Diagnostics?

In July 2020, Sight Diagnostics raised $71M in a D Round. Investors included Koch Disruptive Technologies and Longliv Ventures.

When did Sight Diagnostics receive FDA clearance for its OLO analyzer?

In December 2019, Sight Diagnostics received FDA 510(k) clearance for its OLO analyzer, a device designed to perform blood tests and provide lab-grade results in minutes, including the complete blood count (CBC) panel.

What was a key partnership for Sight Diagnostics in the Gulf Region?

In December 2020, Sight Diagnostics expanded into the Gulf Region through a distribution partnership with Phoenix Capital.

What was a notable deployment of Sight OLO in Europe?

In March 2021, Sight Diagnostics' Sight OLO was deployed at Oxford University's John Radcliffe Hospital in the UK.